ReviewMedical oncology (Northwood, London, England)2025
The emerging role of miR-362 in cancer: expression and function across different cancer types.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cannabidiol modulates exosomal miRNA networks to enhance Imatinib mesylate response in chronic myelogenous leukemia.Global medical genetics · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are essential post-transcriptional regulators of gene expression involved in a broad range of biological activities. Recent studies have increasingly highlighted their significant role in the development and progression of various human cancers. Among these, miR-362 has emerged as a context-dependent molecule, exhibiting both oncogenic and tumor-suppressive functions across different malignancies. Elevated levels of miR-362 have been associated to tumor-promoting effects in several cancers. In contrast, its downregulation in some other carcinoma is associated with disease progression, suggesting a tumor-suppressive role. These opposing functions underscore miR-362 involvement in complex regulatory networks and supports its potential as a biomarker for diagnosis, prognosis, and possibly therapeutic intervention. This review aims to provide an overview of the current understanding of miR-362 expression patterns, molecular targets, regulatory mechanisms, and its dual role in cancer biology, with the goal of clarifying its clinical significance in cancer diagnosis, prognosis, and therapy.
Indexed as
Identifiers
40715910What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.